diaprep systems

What diaprep systems does

DiaPrep System Inc. is a privately held, founder-led public-health consulting firm established in 1996 in Atlanta, Georgia, by Dr. Michael Favorov, an internationally recognized epidemiologist with more than 40 years of experience across infectious disease prevention, vaccine programs, and laboratory quality systems. The company operates as an alliance of partner organizations with locally incorporated entities in Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan, and Ukraine, providing regional delivery infrastructure across Eastern Europe and Central Asia (EECA). Its core offerings fall into four streams: (1) public-health consulting for governments and agencies, including national COVID-19 response planning for the Republic of Uzbekistan and epidemiological program design; (2) scientific and technical support for diagnostic test manufacturers, including assistance with CE Mark, WHO prequalification, and FDA Emergency Use Authorization processes; (3) development of CE-marked serological antibody and antigen tests for SARS-CoV-2 and a COVID-19 vaccine prototype, produced in collaboration with DIA Group partners; and (4) educational and training services delivered through webinars, lectures, and a Knowledge Hub.

DiaPrep's business model is primarily project-based professional services, with engagements sourced through direct advisory relationships and the founder's professional network spanning the U.S. CDC, International Vaccine Institute, and EECA public-health institutions. Diagnostic products are co-developed with DIA Group alliance partners rather than sold through traditional distribution channels, and pricing for services is not publicly disclosed. The technology foundation rests on classical serological and molecular diagnostic methods, including patented techniques for hepatitis detection, point-of-care rapid tests designed for limited-resource settings, and quality control programs for HIV and tuberculosis laboratory diagnostics.

Customer segments are concentrated among governments and public-health agencies (primary), diagnostic test manufacturers (primary), and medical, clinical, research, and educational institutions (secondary). The company carries three U.S. patents held by Dr. Favorov on hepatitis detection methods, holds CE Mark certification for its COVID-19 diagnostics, and relies heavily on Dr. Favorov's personal media presence, scientific publications (100+), and institutional relationships as primary go-to-market channels.

Name

diaprep systems

Legal name

DiaPrep System Inc.

Website

https://diaprepsystem.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1–10 employees

Short description

DiaPrep System is a founder-led public-health consulting firm providing epidemiological advisory, diagnostic test development, and training services to governments, manufacturers, and institutions across Eastern Europe and Central Asia, anchored by Dr. Michael Favorov's 40+ year career.

Ownership category

akta.pro rank

Product category

Public Health Consulting and Diagnostics

NAICS

Medical Laboratories (621511), Scientific Research and Development Services (5417), Public Administration (92)

SIC

Services-Misc Health & Allied Services, Nec (8090), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Immunization & Vaccine Delivery Programs (BPADAIAB)

akta.pro secondary industries

Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI), Syndromic Surveillance & Early Warning Systems (HLAJABAB)

Keywords

• Public health consulting
• Infectious disease diagnostics
• Epidemiological modeling
• Rapid point-of-care testing
• Vaccine development

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Public Health Consulting Services: Consulting on public health issues including program development, evaluation, and implementation of diagnostic strategies for governments and health agencies.
2. Scientific and Technical Support Services: Expert support for diagnostic test system development, technical evaluations, and regulatory compliance assistance (CE, WHO prequalification, FDA EUA).
3. Educational and Training Services: Training programs, webinars, lectures, and educational materials on public health, epidemiology, laboratory diagnostics, and vaccination.
4. Diagnostic Products (CE Marked): Serological antibody and antigen tests for COVID-19 produced in partnership with DIA Group companies, bearing European CE Mark certification.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

DiaPrep System Inc. provides public health consulting, epidemiological modeling, and scientific-technical support services to governments, public health agencies, diagnostic test manufacturers, and the medical community. The company develops serological antibody and antigen tests for COVID-19 and other infectious diseases, supports vaccine prototype development, runs quality control programs for laboratory diagnostics, and delivers educational programs and training in epidemiology and laboratory diagnostics.

Product overview

DiaPrep System Inc. is a public health consulting organization offering a portfolio of diagnostic products and advisory services. The core offerings include serological antibody and antigen tests for COVID-19 developed through the DIA Technical Group, a COVID-19 vaccine prototype in development, and point-of-care rapid diagnostic tests for infectious diseases. These products are complemented by expert consulting services (epidemiological studies, test evaluations, policy development) and educational programs (lectures, webinars, training). The company serves public health agencies, governments, and medical communities primarily in Eastern Europe and Central Asia.

Differentiator

Problem solved

Functional benefit

Brands

• DIA Group: Collaborative network of companies including DiaPrep working together on COVID-19 diagnostics, vaccines, and public health projects
• DiaPrep Alliance

Quantifiable outcome

• Significant reduction in mortality among pregnant women from hepatitis E through developed treatments
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• DIA Group (Companies)coreStrategic or Co-development Partner · 1 January 1996DiaPrep works actively with DIA Group partner organizations on development and production of serological antibody and antigen tests for COVID-19, as well as COVID-19 vaccine prototype development. The collaboration has yielded tests bearing CE Mark certification.
• U.S. Centers for Disease Control and Prevention (CDC)coreOthersDiaPrep team, led by Dr. Favorov, has strong professional ties to U.S. CDC. Dr. Favorov served as CDC Regional Director for Central Asia. DiaPrep has a Material Transfer Agreement (MTA) with CDC for HCV rapid test project. Collaboration on quality control programs for HIV and tuberculosis diagnostics.
• International Universities and Scientific CentersminorOthersCollaboration with expertise from leading scientific institutions and universities in the United States, France, Turkey, and other countries.
• DiaPrep Ukraine (Диапроф-Мед)coreStrategic or Co-development PartnerUkrainian partner company developing and producing COVID-19 serological tests. Currently pursuing FDA certification for their diagnostic products. Collaborated on protein development for antibody tests and vaccine research.
• EZS Events LLP (Kazakhstan)coreChannel Partner/ Reseller/ DistributorAlliance partner in Kazakhstan representing DiaPrep in Central Asian operations. Located in Almaty at 35 Kasteev st.
• LLC DiaPrep UkrainecoreChannel Partner/ Reseller/ DistributorAlliance partner in Ukraine operating from Kiev. One of the primary operational partners for DiaPrep in Eastern Europe.
• LLC Melior (Kyrgyzstan)coreChannel Partner/ Reseller/ DistributorAlliance partner in Kyrgyzstan operating from Bishkek. Part of the DiaPrep Alliance network in Central Asia.
• LLC Dia-Express (Uzbekistan)coreChannel Partner/ Reseller/ DistributorAlliance partner in Uzbekistan operating from Angren. Part of regional operations supporting DiaPrep's work in the country including the national COVID-19 response plan.
• LLC DiaPrep TajikistancoreChannel Partner/ Reseller/ DistributorAlliance partner in Tajikistan operating from Dushanbe. Completes the Central Asian regional coverage for DiaPrep operations.
• International Vaccine Institute (IVI)minorStrategic or Co-development PartnerDr. Favorov served as Deputy Director-General of IVI. Collaboration on vaccination programs against typhoid fever, HPV, cholera, influenza, pneumococcal infection, meningococcal disease, and BCG.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Chemonics International: Large global health and development consulting firm implementing USAID and donor-funded programs in emerging markets. Directly comparable as it provides public health program consulting, including infectious disease control, similar to DiaPrep's government advisory work, but at significantly greater scale.
• FHI 360: International NGO providing public health, infectious disease, and laboratory strengthening services globally. Comparable to DiaPrep in its focus on epidemiology, HIV/hepatitis/tuberculosis programs, and laboratory quality control in resource-limited settings, though operating at much larger scale.
• John Snow, Inc. (JSI): Public health consulting and research organization focused on health systems strengthening in developing countries. Comparable to DiaPrep's consulting engagements with governments on infectious disease programs, immunization, and laboratory capacity building.
• PATH: Global health nonprofit working on vaccines, diagnostics, and infectious disease in low-resource settings. Comparable to DiaPrep's vaccine prototype work and rapid diagnostic development, though PATH operates at much larger scale and across multiple therapeutic areas.
• Clinton Health Access Initiative (CHAI): Global health organization working with governments to strengthen health systems and improve access to vaccines and diagnostics. Comparable to DiaPrep's government advisory model for national COVID-19 and infectious disease response plans.
• Palladium: Global consulting firm implementing international development and health programs across emerging markets. Comparable to DiaPrep's government advisory services and infectious disease program development, particularly across EECA and other emerging market regions.
• IQVIA Emerging Markets: Global health data and consulting firm with significant emerging market presence in diagnostics and public health. Comparable through its work with diagnostic manufacturers on regulatory strategy, market access, and laboratory quality standards in resource-limited countries.

Direct peers

• International Vaccine Institute (IVI): International organization dedicated to vaccine development and delivery for developing countries. Directly comparable through its shared history with DiaPrep's founder (former Deputy Director-General) and overlapping focus on vaccination programs for typhoid, HPV, cholera, and pneumococcal disease in resource-limited settings.

Regional players

• Dalberg Global Development Advisors: Global development consulting firm advising governments, multilaterals, and NGOs on health and development strategy. Comparable to DiaPrep's consulting-driven model for governments, though Dalberg focuses on strategy-level advisory rather than laboratory and diagnostic technical services.

Emerging players

• Epidemico: Epidemiology and public health informatics consultancy focused on infectious disease surveillance and outbreak response. Comparable to DiaPrep's epidemiological modeling and disease surveillance work, though operating primarily through digital health tools and analytics platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/channel/UCGWtKMF1d7TX6tNG6WPlHeg
• Facebookfacebook.com/DiaPrep
• LinkedInlinkedin.com/company/diaprep

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about diaprep systems